
Findings published in the European Journal of Ophthalmology have found that intravitreal bevacizumab (IVB) combined with panretinal photocoagulation in patients with open angle neovascular glaucoma (NVG) can reduce iris and angle neovascularization and temporarily inhibit further PAS formation.
